New drugs 2016, part 2.
Daniel A. Hussar, PhD Remington Professor of Pharmacy Philadelphia College of Pharmacy University of the Sciences Philadelphia, Pa.
Daniel A
DA
Hussar
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use; D002219:Carbamates; D017277:Drug Approval; D004358:Drug Therapy / Q000451:nursing; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D009570:Nitriles / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D011759:Pyrrolidines; D015363:Quinolones / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration; D014633:Valine / Q000031:analogs & derivatives
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001562:Benzimidazoles; D002219:Carbamates; D007093:Imidazoles; D009570:Nitriles; D011725:Pyridines; D011759:Pyrrolidines; D015363:Quinolones; D013876:Thiophenes; D014230:Triazoles; C000591922:brexpiprazole; C098107:flibanserin; C508735:isavuconazole; C000594745:idarucizumab; D014633:Valine; C549273:daclatasvir; C577155:evolocumab; C571059:alirocumab